By Billy Candra 
A landmark study spearheaded by researchers at the University of Cambridge has delivered compelling evidence that bilateral salpingo-oophorectomy (BSO), the surgical removal of the ovaries and fallopian tubes, not only significantly reduces the risk of ovarian cancer in women with particular BRCA1 and BRCA2 genetic variants but also substantially lowers their overall risk of early death. Critically, this extensive research, published in The Lancet Oncology, found no associated increase in long-term adverse health outcomes, such as heart disease, stroke, or depression, challenging previous concerns about early menopause induced by the procedure.
The findings offer profound reassurance to thousands of women worldwide carrying these high-risk genetic mutations, particularly those with a prior history of breast cancer, who face complex decisions about prophylactic surgeries. The study, which leveraged vast electronic health records and genetic testing data from NHS England, represents the first large-scale investigation of its kind into the long-term mortality benefits of BSO in this specific, vulnerable population.
Understanding the Genetic Imperative: BRCA1 and BRCA2 Mutations
To fully appreciate the significance of these findings, it is essential to understand the role of BRCA1 and BRCA2 genes. These genes are tumor suppressors, meaning they normally help repair DNA damage and prevent cells from growing uncontrollably. When a person inherits a harmful mutation in one of these genes, their DNA repair mechanisms are compromised, dramatically increasing their lifetime risk of developing certain cancers, most notably breast and ovarian cancer.
For women in the general population, the lifetime risk of breast cancer is approximately 13%, and for ovarian cancer, it is about 1.2%. However, for carriers of a BRCA1 mutation, the lifetime risk of breast cancer can soar to 40-85%, and ovarian cancer risk can reach 20-44%. For BRCA2 carriers, the lifetime risk for breast cancer is similarly elevated at 40-85%, with ovarian cancer risk at 11-17%. These figures underscore the profound genetic predisposition faced by these individuals, transforming cancer risk from a statistical possibility into a near certainty for many.
Genetic testing for BRCA1 and BRCA2 mutations became more widely available in the mid-1990s, revolutionizing risk assessment and management for at-risk individuals and families. The identification of these mutations opened the door to proactive risk-reduction strategies, including enhanced surveillance, chemoprevention, and prophylactic surgeries. For ovarian cancer, a disease notoriously difficult to detect in its early stages and often diagnosed at advanced, less curable phases, risk-reducing salpingo-oophorectomy (RRSO), or BSO, emerged as a crucial intervention.
The Established Role of BSO in Ovarian Cancer Prevention
For years, medical guidelines have recommended BSO for BRCA1 and BRCA2 carriers to mitigate their elevated ovarian cancer risk. Previous studies have demonstrated that this procedure can reduce the risk of developing ovarian cancer by as much as 80%. The timing of the surgery is critical, generally recommended between the ages of 35 and 40 for BRCA1 carriers and between 40 and 45 for BRCA2 carriers, aligning with the typical onset of ovarian cancer in these populations.
However, despite its proven efficacy in preventing ovarian cancer, BSO has always presented a complex dilemma. The removal of the ovaries, the body’s primary source of estrogen, induces immediate surgical menopause. This can lead to a range of challenging symptoms, including hot flashes, night sweats, sleep disturbances, mood changes, and vaginal dryness, as well as concerns about long-term health consequences like osteoporosis and cardiovascular disease. For BRCA1 and BRCA2 carriers with a history of breast cancer, the situation is further complicated by the fact that hormone replacement therapy (HRT), often used to manage menopausal symptoms, is typically contraindicated due to concerns about potentially stimulating breast cancer recurrence. This leaves many women navigating early menopause without the standard symptomatic relief, raising questions about their overall quality of life and long-term health.
Navigating Ethical Boundaries: A Novel Research Approach
Traditionally, the "gold standard" for evaluating the efficacy and safety of medical interventions is a randomized controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the treatment or a placebo/standard care, allowing researchers to isolate the effects of the intervention. However, conducting an RCT for BSO in BRCA1 and BRCA2 carriers would be ethically indefensible. Randomly assigning some women to not receive a procedure known to drastically reduce a deadly cancer risk would deliberately expose them to substantially greater harm.
Faced with this ethical imperative, the Cambridge research team, in collaboration with the National Disease Registration Service (NDRS) in NHS England, pioneered a different approach. They leveraged the immense power of electronic health records and data from NHS genetic testing laboratories, meticulously collected and curated by the NDRS. This allowed them to conduct a large-scale, retrospective cohort study, examining the long-term outcomes of BSO among BRCA1 and BRCA2 pathogenic variant (PV) carriers who had previously been diagnosed with breast cancer. This innovative methodology provided a robust alternative to an RCT, offering real-world insights into the procedure’s impact.
Key Findings: A Substantial Reduction in Early Mortality
The study identified a substantial cohort of 3,400 women, roughly split between BRCA1 and BRCA2 carriers (approximately 1,700 for each variant), all of whom had a history of breast cancer. Among these, around 850 BRCA1 carriers and 1,000 BRCA2 carriers had undergone BSO. The median follow-up period for the study was 5.5 years, providing sufficient time to observe significant long-term outcomes.
The results were unequivocally positive: women who underwent BSO were approximately half as likely to die from cancer or any other cause during the follow-up period. This mortality reduction was particularly pronounced in BRCA2 carriers, who experienced a 56% reduction in early death risk, compared to a 38% reduction in BRCA1 carriers. Furthermore, the study revealed that women who had BSO were also at a roughly 40% lower risk of developing a second primary cancer.
While the researchers acknowledge the inherent limitations of observational studies in establishing definitive causality, the strength and consistency of the evidence strongly point towards BSO being the driving factor behind these improved survival rates. The meticulous design, large cohort size, and comprehensive data analysis lend significant weight to their conclusions.
Dispelling Long-Standing Concerns: No Increased Risk of Adverse Effects
One of the most crucial aspects of the Cambridge study’s findings is the absence of a link between BSO and an increased risk of other long-term health outcomes often associated with early menopause. Previous research on the general population had suggested a potential association between surgical menopause and increased risks of conditions like heart disease, stroke, and depression. However, for BRCA1 and BRCA2 carriers with a history of breast cancer, this study found no such correlation following BSO. This particular finding offers immense relief and clarity, especially for women unable to take HRT. It suggests that the benefits of cancer risk reduction far outweigh any generalized concerns about early menopause in this specific, high-risk group.
Hend Hassan, a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, and the study’s first author, articulated the significance: "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes. Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."
Addressing Health Disparities: A Call for Equitable Access
Beyond the clinical outcomes, the study also cast a spotlight on critical health disparities in BSO uptake. The data revealed that most women undergoing BSO were white, and importantly, Black and Asian women were approximately half as likely to have the procedure compared to white women. Furthermore, women residing in less deprived areas showed a greater propensity to undergo BSO than those in the most-deprived categories.
These findings highlight a concerning inequity in access to and utilization of a life-saving procedure. The reasons behind these disparities are likely multifaceted, encompassing factors such as differences in awareness of genetic risk, access to genetic counseling and testing, cultural beliefs, communication barriers, socioeconomic status impacting healthcare access, and systemic biases within healthcare systems.
Hassan emphasized the urgency of addressing these disparities: "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women." This calls for targeted public health initiatives, culturally sensitive patient education, improved access to genetic services, and efforts to dismantle systemic barriers that prevent equitable access to preventative care.
Implications for Clinical Practice and Patient Counseling
The robust evidence from this Cambridge study is poised to significantly impact clinical practice and patient counseling for BRCA1 and BRCA2 carriers. Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, affirmed: "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation."
For women already diagnosed with breast cancer and carrying these mutations, the decision to undergo BSO can be particularly agonizing. They have already faced one cancer diagnosis and may be grappling with ongoing treatment or recovery, alongside the fear of a second primary cancer. This study provides concrete, reassuring data that BSO offers not just ovarian cancer prevention but also a significant overall survival advantage, without adding other serious health risks. This empowers healthcare providers to offer clearer, more confident recommendations, facilitating truly informed shared decision-making with their patients.
The findings are likely to reinforce and potentially strengthen existing clinical guidelines for risk-reducing surgery in these populations, ensuring that BSO remains a cornerstone of preventative care.
The Power of NHS Data and Future Directions
Professor Antoniou, who also serves as Director of the Cancer Data-Driven Detection programme, underscored the methodological triumph of the study: "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." The ability to harness real-world, routinely collected health data on such a large scale, while respecting patient privacy, is a testament to the strength and potential of integrated healthcare systems like the NHS. This approach offers a model for future research into complex health questions where traditional RCTs are not feasible.
The research was generously funded by Cancer Research UK, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, reflecting the collaborative effort and significant investment in this critical area of cancer research.
Looking ahead, the University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for a new hospital, the Cambridge Cancer Research Hospital. This ambitious project, a partnership with Cambridge University Hospitals NHS Foundation Trust, aims to transform cancer diagnosis and treatment across the East of England and beyond. The insights gleaned from studies like this one will directly inform the advanced care and innovative research conducted within such a facility, ultimately changing the lives of cancer patients nationwide and globally.
Further research will undoubtedly focus on understanding and overcoming the identified disparities in BSO uptake. Investigating specific barriers within different racial and socioeconomic groups, developing targeted educational materials, and implementing culturally competent counseling strategies will be vital next steps to ensure that all eligible women can benefit from this life-extending procedure. The Cambridge study marks a significant step forward, providing clarity and hope for women at the highest genetic risk of cancer.
